

Scheme 2 Synthesis of imidazo[1,2-a]pyridines from **1a**.Fig. 1 Structures of the cations of **3a**·HCl·H₂O (left) and **4a**·HCl·2H₂O (right), with 40% probability displacement ellipsoids; N atoms are shown with shading.

regioselectivity of arylimidazo[1,2-*a*]pyridine formation; it was also found that the outcome of the reaction could be manipulated through substrate concentration. This study highlights a dynamic solution state for alkynyliodonium salt derivatives and that, through control of experimental conditions, access to a plethora of substituted heteroaromatics may be achieved, with alternative regioisomers possible from the same starting material.

In 2004 Liu and co-workers reported the synthesis of a range of 2-arylimidazo[1,2-*a*]pyridines (*cf.* **3a**) from the reaction of alkynyliodonium tosylates and 2-aminopyridine.⁴⁰ Surprisingly, the analogous reaction of **1a** afforded both 2- and 3-substituted imidazo[1,2-*a*]pyridines in roughly equal amounts (Scheme 2), as confirmed by X-ray crystallography (ESI† and Fig. 1).

This intriguing production of two regioisomers led us to repeat the procedure reported by Liu and co-workers⁴⁰ using the tosylate, **5**, to confirm that just one regioisomer had indeed been produced. In our hands, the experiment showed that the major product of the reaction was in fact **4a** and that, although this was dominant, trace amounts of **3a** were also present (2%, **3a**:44%, **4a**); comparison of the ¹H-NMR data with other reports supports this regiochemical assignment.^{41–44} Having optimized the reaction shown in Scheme 2 for a range of solvents and bases (see ESI†), fluoro-benzene (PhF) (to minimise intermolecular insertion) and K₂CO₃ were chosen respectively, and at room temperature to minimize decomposition of the alkynyliodonium salts.

Heterogeneous bases and aprotic,⁴⁵ non-coordinating solvents gave the best results. Despite slightly lower yields, PhF was chosen as it resulted in a ‘cleaner’ reaction facilitating isolation of the products. Comparison with other alkynyliodonium salts showed that **3a** was undetectable using the triflate (**6**), whereas the cyclic iodane, **7** (see ESI†), produced a ratio of products between that observed for the trifluoroacetate and tosylate salts (Table 1). Only the phenyliodonium derivatives were investigated since variation of the second aromatic ring was previously found to have no effect in the preparation of 2-arylfuro[3,2-*c*]pyridines.³⁸

Table 1 Counter-ion dependence for the reaction of phenyl(phenylethynyl)iodonium salts and **2**

Ar, X	Ratio 3a : 4a	Total yield ^a (%)
Ph, TFA (1a)	73 : 27	49 ^b
Ph, OTs (5)	7 : 93	62
Ph, OTf (6)	0 : 100	58
C ₆ H ₄ -2-CO ₂ ⁻ , - (7) ^c	37 : 63	54


^a Isolated yields. ^b Mean of 3 syntheses. ^c Temp. raised to reflux after 14 h.

Such a dependence on the anion used has never been reported previously in the formation of heteroaromatics from alkynyliodonium salts, though the literature suggests that the conversion of alkynyliodonium salts to alkenyliodonium salts appears to demonstrate stereoselectivity for the *E*- or *Z*-isomer depending on the counter-ion used.^{45–55} The influence of solvent on ion pair separation, and hence choice of counter-ion, has also been shown to affect the reactions of diaryliodonium salts.⁵⁶

In addition to the counter-ion dependence of the reaction it was found that the concentration of the reactants also exerted an unexpected degree of control over the product distribution (Table 2 and Fig. 2).

It should be noted that **1a** was soluble in DCM and CHCl₃ at all the concentrations tested, though not in PhF; however, in all three solvents, rapid dissolution of **1a** was observed on addition of **2**. Under the reaction conditions outlined in Scheme 1 the K₂CO₃ remained as a solid throughout. This suggests that the key reactive species is generated *in situ* as the same concentration dependence was observed for all three solvents (see ESI†).

Although some increase in yield was observed at higher dilutions, far more noticeable was the concentration-dependent regioselectivity favouring the 2-substituted regioisomer, **3a**. To confirm this unexpected dependence, reactions were conducted using five different iodonium salt concentrations (Table 2 and Fig. 2). This ‘tuning’ of the reaction conditions has potential value, for example in drug discovery, where both regioisomers are accessible from a single set of reagents.

Table 2 Concentration dependence for the reaction of **1a** and **2**

[1a] (mol L ⁻¹)	Ratio 3a : 4a	Total yield ^{a,b,c} (%)
0.01	90 : 10	49
0.02	73 : 27	49
0.11	39 : 61	50
0.50	26 : 74	34
1.00	17 : 83	38

^a Isolated yields. ^b Mean of 3 syntheses. ^c 5 mmol scale.






Fig. 2 Concentration dependence for the reaction of **1a** and **2**.

To establish whether the observed concentration dependence was restricted to the production of phenylimidazo[1,2-*a*]pyridines (**3a** and **4a**) several alternative alkyliodonium salts were also studied (**1b–1d**) and it was pleasing to note that a similar trend was found (Table 3).

The mechanism of imidazopyridine formation presented by Liu⁴⁰ follows that previously reported by Wipf⁵⁷ (and later Togo³⁰) for the formation of thiazoles. An alternative route to the observed product has also been proposed by Ochiai.⁵⁸ All of these options invoke a monomeric form of the aryl(alkynyl)iodonium salt as the starting species even though kinetic and spectroscopic evidence for other hypervalent iodine compounds has been reported that indicates the presence, in solution, not only of associated counter-ions, but also of higher-order structures (dimers, oligomers *etc.*).^{59–61} Such species have also been shown to be highly concentration-dependent^{60,61} and therefore contributions from these structures cannot be ruled out.

In addition these proposals rapidly result in loss of the counter-ion. However, to retain the influence of this component, and taking into account these prior mechanistic studies, we propose that intermediates such as **9** and **14** (Fig. 3) and **8** and **13** (Fig. 4) should also be considered in the mechanistic rationale since both the amino- and pyridinyl-nitrogen atoms of 2-aminopyridine are viable nucleophiles⁶² (Scheme 3: there may also be influence of the counter-ion in the subsequent steps due to the charged nature of the proposed intermediates).

Table 3 Concentration dependence for the reaction of **1b–1d** and **2**

Ar	[1] (mol L ⁻¹)	Ratio 3 : 4 ^a	Total yield ^b (%)
4-Methylphenyl (1b)	0.02	74 : 26	66
4-Methylphenyl (1b)	0.10	44 : 54	63
3'-Thienyl (1c)	0.02	84 : 16	60
3'-Thienyl (1c)	0.14	57 : 43	58
4-Bromophenyl (1d)	0.02	81 : 19	78
4-Bromophenyl (1d)	0.14	53 : 47	55

^a 2.5 mmol scale. ^b Isolated yields.




Fig. 3 Proposed [10-1-4] intermediates, **14** and **18**.




Fig. 4 Potential intermediates of Michael addition.

Further complexity is introduced following alkyldiene carbene formation (the carbene can either cyclize directly or undergo 1,2-migration prior to cyclization), resulting in the formation of **3a** or **4a** *via* several different pathways.

As the acetylenic products of 1,2-migration have been reported to be highly reactive,^{58,63} especially within a basic environment, they may prove difficult to observe and as such we prepared the isotopically labelled [7-¹³C]-**1a** to investigate the process.

This preliminary ¹³C-labelling study generated [2-¹³C]-**3a** and [3-¹³C]-**4a** as expected (Scheme 3); however, the isotopomer [3-¹³C]-**3a** was also present, highlighting that a competitive 1,2-migration was occurring (Scheme 4) and suggesting that at least three reaction pathways are in operation.

Conclusions


In summary, we have presented the first example of regiochemical control in the synthesis of heteroaromatics from alkyliodonium salts. A protocol based on the counter-ion and concentration dependence of the process has been identified for the selective formation of 2-arylimidazo[1,2-*a*]pyridines and 3-arylimidazo[1,2-*a*]pyridines. In addition, initial studies using carbon-13 labelled substrates have demonstrated that, even though well studied, the reactions of alkyliodonium salts are highly complex and that multiple mechanistic processes appear to be underway simultaneously.

This new-found understanding is being applied to the preparation of a diverse range of heterocyclic ring systems which are of interest to our drug discovery programmes. Further work to resolve and differentiate the many mechanistic options is on-going.


Experimental

Reactions requiring anhydrous conditions were performed using oven- or flame-dried glassware and conducted under a





Scheme 3 Distribution of products from the reaction of [7'-¹³C]-1.



Scheme 4 Mechanism of isotopomer formation; [3-¹³C]-3a.

positive pressure of nitrogen. Anhydrous solvents were prepared thus: DCM and MeCN were refluxed over CaH₂; THF, ether and hexane were refluxed over sodium/benzophenone; toluene was refluxed over sodium; and dibromomethane, chloroform, 1,4-dioxane and fluorobenzene were stored over 3 Å molecular sieves. Infrared spectra were recorded on a Varian Scimitar Series 800 FT-IR with internal calibration. ¹H and ¹³C-NMR spectra were recorded on a Bruker Advance 300 MHz spectrometer, a Jeol ECS 400 MHz spectrometer or a Jeol Lamda 500 MHz spectrometer with residual tetramethylsilane solvent as the reference for ¹H and ¹³C. All coupling constants are given in Hz. Elemental analyses were carried out at London Metropolitan University. Mass spectrometry was recorded at the EPSRC Mass Spectrometry Service, Swansea or on a Waters LCT Premier (TOF-MS) operating in 'W' mode. Melting points were recorded on a Gallenkamp MF-370 melting point apparatus and are uncorrected. Automated flash chromatography was performed using a Varian IntelliFlash 971-FP discovery scale flash purification system. The terms 'ether' and 'petrol' refer to diethyl ether and the fractions boiling between 40 and 60 °C (unless otherwise specified) respectively. X-ray crystallographic data were measured on an Agilent Technologies Gemini A Ultra diffractometer at 150 K, using Mo or CuKα radiation; full details are in the ESI† and deposited with CCDC.

CAUTION: Some hypervalent iodanes are *potentially* explosive and should be handled taking appropriate precautions.^{64–67}

2-Phenylimidazo[1,2-*a*]pyridine (3a)^{40,68,69}

K₂CO₃ (1.05 g, 7.62 mmol) and 2 (0.31 g, 3.27 mmol) were stirred together in dry PhF (250 mL) for 45 min before the addition of 1a (1.05 g, 2.51 mmol) by powder funnel. The solution was then stirred in darkness, at RT, under nitrogen overnight before being washed with water (300 mL) and extracted into DCM (2 × 75 mL). The organic fractions were dried (MgSO₄) and concentrated *in vacuo* to give a brown oil. The crude product was purified by column chromatography (SiO₂, Grace Resolve™ 80 g cartridge;§ sample loaded in DCM, 1:0 hexane–ether for 5 min then increasing to 3:7 over 120 min and holding at this solvent mixture until elution was complete) to give the product as a white crystalline solid (0.24 g, 1.22 mmol, 49%). Mp 132–133 °C (from DCM–petrol) (lit.,⁷⁰ 136–137 °C from cyclohexane); R_f 0.55 (4:1 ether–petrol); Found: C, 80.4; H, 5.3; N, 14.4. Calc. for C₁₃H₁₀N₂: C, 80.4; H, 5.2; N, 14.4%; IR ν_{max}/cm⁻¹ (neat) 3130, 1632, 1502, 1475, 1447, 1369, 1353, 1304, 1273, 1246, 1203, 1145, 1077, 1027; δ_H (300 MHz, CDCl₃; Me₄Si) 8.10 (1H, d, H5 J 6.9), 7.97 (2H, d, H2'/H6' J 7.2), 7.85 (1H, s, H3), 7.65 (1H, d, H8 J 9.0), 7.45 (2H, t_{app.}, H3'/H5' J 7.5), 7.34 (1H, t, H4' J 7.5), 7.17 (1H, t_{app.}, H7 J 6.9), 6.77 (1H, t_{app.}, H6 J 6.0); δ_C (75 MHz, CDCl₃; Me₄Si) 146.41 (C2), 146.09 (C9), 134.27 (C1'), 128.99 (C3'/C5'), 128.27 (C4'), 126.55 (C2'/C6'), 125.86 (C5), 124.79 (C7), 118.00 (C8), 112.66 (C6), 108.38 (C3); m/z (CI) 195 ([M + H]⁺, 100%), 95 (3), 80 (2), 52 (4). Found: [M + H]⁺, 195.0917. C₁₃H₁₁N₂ requires 195.0917.

3-Phenylimidazo[1,2-*a*]pyridine (4a)^{43,71}

Using K₂CO₃ (2.15 g, 15.55 mmol), 2-aminopyridine (0.61 g, 6.50 mmol), PhF (5 mL) and 1a (2.07 g, 4.95 mmol). White crystalline solid (0.36 g, 1.84 mmol, 37%). Mp 95–97 °C (from

§ Although several column packings were evaluated, *e.g.* reverse phase silica, alumina (neutral, basic and acidic), with a range of solvents and additives, the Grace cartridges were found to provide satisfactory purification.



MeOH–H₂O) (lit.,⁷¹ 97–98 °C from petroleum ether); *R*_f 0.13 (4 : 1 ether–petrol); Found: C, 80.3; H, 5.1; N, 14.3. Calc. for C₁₃H₁₀N₂: C, 80.4; H, 5.2; N, 14.4%; IR $\nu_{\max}/\text{cm}^{-1}$ (neat) 1634, 1603, 1540, 1499, 1480, 1450, 1442, 1352, 1296, 1272, 1262, 1175, 1148, 1134, 1074, 1009; δ_{H} (400 MHz, d₆-DMSO; Me₄Si) 8.45 (1H, d, H₅ *J* 6.9), 7.72 (1H, s, H₂), 7.61 (1H, d, H₈ *J* 8.7), 7.57 (2H, d, H₂'/H₆' *J* 7.3), 7.46 (2H, t_{app.}, H₃'/H₅' *J* 7.8), 7.34 (1H, t, H₄' *J* 7.4), 7.21 (1H, t_{app.}, H₇ *J* 7.8), 6.86 (1H, t_{app.}, H₆ *J* 6.6); δ_{C} (100 MHz, d₆-DMSO; Me₄Si) 146.06 (C₉), 133.07 (C₂), 129.74 (C₃/C₅'), 129.42 (C₁'), 128.37 (C₄'), 127.97 (C₂'/C₆'), 125.58 (C₃), 125.00 (C₇), 124.45 (C₅), 118.09 (C₈), 113.30 (C₆); *m/z* (ESI) 195 ([M + H]⁺, 100%). Found: [M + H]⁺, 195.0905. C₁₃H₁₁N₂ requires 195.0922.

2-(4'-Methylphenyl)imidazo[1,2-*a*]pyridine (3b)^{69,72}

Using K₂CO₃ (1.09 g, 7.89 mmol), **2** (0.32 g, 3.39 mmol), PhF (113 mL) and **1b** (1.11 g, 2.56 mmol). White crystalline solid (0.26 g, 1.25 mmol, 49%) (as well as **4b** (17%)). Mp 138–140 °C (from acetone) (lit.,⁷² 145–146 °C); *R*_f 0.23 (4 : 1 ether–petrol); Found: C, 80.9; H, 5.7; N, 13.4. Calc. for C₁₄H₁₂N₂: C, 80.7; H, 5.8; N, 13.5%; IR $\nu_{\max}/\text{cm}^{-1}$ (neat) 3132, 1633, 1506, 1483, 1372, 1349, 1268, 1245, 1202, 1139; δ_{H} (500 MHz, CDCl₃; Me₄Si) 8.05 (1H, dt_{app.}, H₅ *J* 6.8, *J* 1.2), 7.84 (2H, d, H₃'/H₅' *J* 8.1), 7.77 (1H, s, H₃), 7.60 (1H, dd, H₈ *J* 9.1, *J* 0.8), 7.23 (2H, d, H₂'/H₆' *J* 8.1), 7.12 (1H, ddd, H₇ *J* 9.1, *J* 6.8, *J* 1.3), 6.71 (1H, dt_{app.}, H₆ *J* 6.8, *J* 1.1), 2.38 (3H, s, Me); δ_{C} (125 MHz, CDCl₃; Me₄Si) 145.86, 145.55, 137.72, 130.89, 129.36, 125.90, 125.45, 124.41, 117.36, 112.21, 107.69, 21.22; *m/z* (ESI) 209 ([M + H]⁺, 100%). Found: [M + H]⁺, 209.1071. C₁₄H₁₃N₂ requires 209.1073.

3-(4'-Methylphenyl)imidazo[1,2-*a*]pyridine (4b)

Using K₂CO₃ (1.06 g, 7.65 mmol), **2** (0.31 g, 3.29 mmol), PhF (24 mL) and **1b** (1.07 g, 2.47 mmol). White crystalline solid (0.18 g, 0.88 mmol, 36%) (as well as **3b** (27%)). Mp 84–86 °C (from DCM–ether); *R*_f 0.09 (4 : 1 ether–petrol); Found: C, 80.9; H, 5.7; N, 13.4. Calc. for C₁₄H₁₂N₂: C, 80.7; H, 5.8; N, 13.5%; IR $\nu_{\max}/\text{cm}^{-1}$ (neat) 2981, 1634, 1545, 1490, 1353, 1295, 1255, 1166, 1148, 1013; δ_{H} (500 MHz, CDCl₃; Me₄Si) 8.30 (1H, dt_{app.}, H₅ *J* 6.9, *J* 1.2), 7.66 (1H, overlapped s, H₂), 7.65 (1H, overlapped d, H₈ *J* 8.0), 7.44 (2H, d, H₃'/H₅' *J* 8.0), 7.32 (2H, dd, H₂'/H₆' *J* 8.0, *J* 0.6), 7.17 (1H, ddd, H₆ *J* 9.1, *J* 6.9, *J* 1.3), 6.78 (1H, td_{app.}, H₇ *J* 6.9, *J* 1.2), 2.43 (3H, s, Me); δ_{C} (125 MHz, CDCl₃; Me₄Si) 145.99, 138.13, 132.28, 129.88, 128.00, 126.36, 125.73, 123.94, 123.34, 118.21, 112.34, 21.27. *m/z* (ESI) 209 ([M + H]⁺, 100%). Found: [M + H]⁺, 209.1072. C₁₄H₁₃N₂ requires 209.1073.

2-(3'-Thienyl)imidazo[1,2-*a*]pyridine (3c)

Using K₂CO₃ (1.06 g, 7.64 mmol), **2** (0.32 g, 3.36 mmol), PhF (113 mL) and **1c** (1.03 g, 2.43 mmol). White crystalline solid (0.25 g, 1.21 mmol, 50%) (as well as **4c** (10%)). Mp 163–165 °C (from acetone); *R*_f 0.12 (4 : 1 ether–petrol); Found: C, 66.1; H, 3.9; N, 13.8. Calc. for C₁₁H₈N₂S: C, 66.0; H, 4.0; N, 14.0%; IR $\nu_{\max}/\text{cm}^{-1}$ (neat) 3124, 1632, 1508, 1476, 1338, 1306, 1272, 1242, 1144, 1090; δ_{H} (500 MHz, d₆-DMSO; Me₄Si) 8.49 (1H, d,

H₅ *J* 6.7), 8.23 (1H, s, H₃), 7.89 (1H, d, H₂' *J* 2.8), 7.61–7.55 (2H, m, H₄'/H₅'), 7.54 (1H, d, H₈ *J* 9.0), 7.21 (1H, t_{app.}, H₇ *J* 6.6), 6.86 (1H, t_{app.}, H₆ *J* 6.7); δ_{C} (125 MHz, d₆-DMSO; Me₄Si) 144.94, 141.44, 136.38, 127.16, 127.07, 126.46, 125.15, 121.43, 116.76, 112.46, 109.31; *m/z* (ESI) 201 ([M + H]⁺, 100%). Found: [M + H]⁺, 201.0480. C₁₁H₉N₂S requires 201.0481.

3-(3'-Thienyl)imidazo[1,2-*a*]pyridine (4c)

Using K₂CO₃ (1.07 g, 7.76 mmol), **2** (0.32 g, 3.36 mmol), PhF (24 mL) and **1c** (1.05 g, 2.48 mmol). White crystalline solid (0.12 g, 0.62 mmol, 25%) (as well as **3c** (33%)). Mp 54–57 °C (from DCM); *R*_f 0.06 (4 : 1 ether–petrol); IR $\nu_{\max}/\text{cm}^{-1}$ (neat) 3090, 1690, 1637, 1576, 1501, 1483, 1343, 1330, 1299, 1264, 1225, 1169, 1154, 1128, 1087, 1019; δ_{H} (500 MHz, d₆-DMSO; Me₄Si) 8.61 (1H, d, H₅ *J* 7.0), 7.93 (1H, dd, H₂' *J* 1.7, *J* 1.3), 7.85 (1H, s, H₂), 7.76 (1H, dd, H₅' *J* 5.0, *J* 2.1), 7.64 (1H, d, H₈ *J* 8.5), 7.54 (1H, dd, H₄' *J* 5.0, *J* 1.3), 7.29 (1H, ddd, H₇ *J* 8.5, *J* 6.7, *J* 1.7), 6.99 (1H, td_{app.}, H₆ *J* 6.8, *J* 1.1); δ_{C} (125 MHz, d₆-DMSO; Me₄Si) 145.18, 132.58, 128.97, 127.20, 127.08, 124.57, 124.27, 121.18, 121.06, 117.40, 112.88; *m/z* (ESI) 201 ([M + H]⁺, 100%). Found: [M + H]⁺, 201.0479. C₁₁H₉N₂S requires 201.0481.

2-(4'-Bromophenyl)imidazo[1,2-*a*]pyridine (3d)⁷³

Using K₂CO₃ (0.96 g, 6.91 mmol), **2** (0.28 g, 2.95 mmol), PhF (102 mL) and **1d** (1.13 g, 2.27 mmol). White crystalline solid (0.29 g, 1.47 mmol, 65%) (as well as **4d** (13%)). Mp 196–198 °C (from acetone) (lit.,⁷³ 215–216 °C from heptane); *R*_f 0.34 (4 : 1 ether–petrol); Found: C, 57.3; H, 3.2; N, 10.1. Calc. for C₁₃H₉BrN₂: C, 57.2; H, 3.3; N, 10.3%; IR $\nu_{\max}/\text{cm}^{-1}$ (neat) 2955, 2924, 1679, 1635, 1428, 1401, 1371, 1321, 1203, 1065, 1006; δ_{H} (500 MHz, d₆-DMSO; Me₄Si) 8.51 (1H, dt_{app.}, H₅ *J* 6.8, *J* 1.2), 8.42 (1H, s, H₃), 7.91 (2H, d, H₃'/H₅' *J* 8.7), 7.61 (2H, d, H₂'/H₆' *J* 8.7), 7.56 (1H, dd, H₈ *J* 9.1, *J* 1.0), 7.24 (1H, ddd, H₇, *J* 9.1, *J* 6.8, *J* 1.3), 6.89 (1H, td_{app.}, H₆ *J* 6.8, *J* 1.0); δ_{C} (125 MHz, d₆-DMSO; Me₄Si) 144.82, 143.13, 133.16, 131.55, 127.47, 126.87, 125.11, 120.59, 116.61, 112.34, 109.42; *m/z* (ESI) 275 ([⁸¹Br][M + H]⁺, 97%), 273 ([⁷⁹Br][M + H]⁺, 100%). Found: [M + H]⁺, 273.0026. C₁₃H₁₀BrN₂ requires 273.0022.

3-(4'-Bromophenyl)imidazo[1,2-*a*]pyridine (4d)⁶⁹

Using K₂CO₃ (1.04 g, 7.55 mmol), **2** (0.31 g, 3.29 mmol), PhF (24 mL) and **1d** (1.23 g, 2.48 mmol). White crystalline solid (0.18 g, 0.65 mmol, 26%) (as well as **3d** (29%)). Mp 89–92 °C (from acetone); *R*_f 0.25 (4 : 1 ether–petrol); Found: C, 57.1; H, 3.2; N, 10.2. Calc. for C₁₃H₉BrN₂: C, 57.2; H, 3.3; N, 10.3%; IR $\nu_{\max}/\text{cm}^{-1}$ (neat) 3023, 1537, 1499, 1478, 1398, 1351, 1303, 1291, 1264, 1174, 1151, 1101, 1074, 1007; δ_{H} (500 MHz, CDCl₃; Me₄Si) 8.25 (1H, dt_{app.}, H₅ *J* 7.0, *J* 1.2), 7.67 (1H, s, H₂), 7.66 (1H, d, H₈ *J* 9.1, *J* 1.1), 7.62 (2H, d, H₂'/H₆' *J* 8.6), 7.40 (2H, d, H₃'/H₅' *J* 8.6), 7.19 (1H, ddd, H₇ *J* 9.1, *J* 6.7, *J* 1.3), 6.80 (1H, td_{app.}, H₆ *J* 6.8, *J* 1.1); δ_{C} (125 MHz, CDCl₃; Me₄Si) 146.24, 132.68, 132.38, 129.35, 128.15, 124.49, 124.39, 123.06, 122.05, 118.29, 112.76; *m/z* (ESI) 275 ([⁸¹Br][M + H]⁺, 98%), 273 ([⁷⁹Br][M + H]⁺, 100%). Found: [M + H]⁺, 273.0026. C₁₃H₁₀BrN₂ requires 273.0022.



1',1'-Dibromo-2'-[¹³C]-styrene ([¹³C]-19)⁷⁴

Triphenylphosphine (5.04 g, 19.22 mmol) and dry carbon tetrabromide (3.10 g, 9.34 mmol) were dissolved in dry DCM (30 mL) at 0 °C under an atmosphere of nitrogen. The solution was stirred for 30 minutes before the dropwise addition of benzaldehyde [¹³C]-carbonyl (0.50 g, 4.67 mmol) over 5 minutes. The solution was stirred at 0 °C for 1 hour before washing with an aqueous 5 M solution of CuSO₄ (300 mL) followed by extraction into DCM (3 × 50 mL). The organic layers were combined, dried (MgSO₄) and concentrated *in vacuo*. The resulting orange oily solid was dry loaded onto silica and purified by column chromatography (silica) to give the product as a pale orange clear oil which crystallized on standing (1.21 g, 4.60 mmol, 98%). *R*_f 0.74 (petrol 40/60); δ_H (300 MHz, CD₂Cl₂; Me₄Si) 7.50–7.39 (2H, m), 7.44 (1H, d, *J* 159.07), 7.33–7.23 (3H, m); δ_C (75 MHz, CD₂Cl₂; Me₄Si) 137.86 (C1'-label). *m/z* (EI) 265 ([⁸¹Br, ⁸¹Br]⁺, 8%), 263 ([⁸¹Br, ⁷⁹Br]⁺, 18%), 261 ([⁷⁹Br, ⁷⁹Br]⁺, 8%), 184 (18), 182 (18), 103 (100). Found: M⁺, 260.8868. C₇¹³C₁ H₆⁷⁹Br₂ requires 260.8864.

Phenyl-α-[¹³C]acetylene ([¹³C]-20)⁷⁴

1',1'-Dibromo-2'-[¹³C]-styrene ([¹³C]-20) (1.21 g, 4.60 mmol) was dissolved in dry ether (30 mL) and cooled to –78 °C under an atmosphere of nitrogen. *n*-Butyllithium (2.17 M in hexanes, 5.41 mL, 11.75 mmol) was added dropwise over 10 minutes and the solution stirred for a further 30 minutes then for 1 hour at room temperature. The reaction was quenched with water (50 mL), washed with water (50 mL) and extracted into ether (3 × 50 mL). The organic layers were combined, dried (MgSO₄) and concentrated *in vacuo* to give the product as a pale yellow oil (0.46 g, 4.43 mmol, 96%)[†] with sufficient purity to be used in subsequent reactions. δ_H (300 MHz, CDCl₃; Me₄Si) 7.54–7.49 (2H, m), 7.37–7.34 (3H, m), 3.09 (1H, d, *J* 49.52); δ_C (75 MHz, CDCl₃; Me₄Si) 84.05 (C1'-label). *m/z* (EI) 103 ([M]⁺, 100%). Found: M⁺, 103.0496. C₇¹³C₁H₆ requires 103.0498.

Phenyl(phenyl-β-[¹³C]-ethynyl)iodonium trifluoroacetate ([¹³C]-1a)

Trifluoroacetic acid (1.01 g, 8.82 mmol) was added dropwise at –30 °C to a stirred solution of phenyliodonium bis(acetate) (1.35 g, 4.20 mmol) in dry DCM (25 mL) over a period of 10 minutes. After a further 30 minutes the solution was allowed to warm to room temperature and stirred for 1 hour before being re-cooled to –30 °C for the injection of a solution of phenyl[α-¹³C]acetylene, [¹³C]-20, (0.46 g, 4.43 mmol) in dry DCM (5 mL) over 5 minutes. The resulting mixture was then allowed to reach room temperature over 3.5 hours in darkness before concentration *in vacuo* (to about 5 mL) followed by crystallization to give the product as a white, crystalline solid (0.63 g, 1.50 mmol, 36%). Mp 79–81 °C (dec.) (from DCM-ether-petrol) δ_H (400 MHz, CDCl₃; Me₄Si) 8.14 (2H, d, H2/H6, *J* 8.7), 7.58 (1H, dt, H4, *J* 7.8, *J* 0.9), 7.49–7.39 (5H, m), 7.34 (2H, t, H3/H5 *J* 7.3); δ_C (100 MHz, CDCl₃; Me₄Si) 162.55 (q, (CO

J 36.2), 133.55 (s, C2/C6), 132.90 (d, C3'/C5', *J* 2.4), 132.14 (s, C3/C5), 131.96 (s, C4), 130.86 (d, C4', *J* 1.4), 128.72 (d, C2'/C6', *J* 5.5), 120.67 (s, C1), 120.40 (d, C1', *J* 86.2), 104.10 (s, C7'-label), 45.14 (d, C8', *J* 160.6); *m/z* (ESI) 306 ([M – TFA]⁺, 100%), 294 (14), 179 (19). Found: [M – TFA]⁺, 305.9861. C₁₃¹³C₁ H₁₀I requires 305.9855.

2-Phenyl-2/3-[¹³C]-imidazo[1,2-*a*]pyridine ([¹³C]-3a) and 3-phenyl-3-[¹³C]-imidazo[1,2-*a*]pyridine ([¹³C]-4a)

Potassium carbonate (0.30 g, 2.18 mmol) and 2-aminopyridine (0.09 g, 0.97 mmol) were stirred together in dry fluorobenzene (6.3 mL) for 45 minutes under an atmosphere of nitrogen before the addition of phenyl(phenyl[β-¹³C]ethynyl)iodonium trifluoroacetate (0.30 g, 0.70 mmol) by powder funnel. The solution was then stirred in darkness, at room temperature, overnight before being washed with water (150 mL) and extracted into DCM (4 × 30 mL). The organic fractions were combined, dried (NaSO₄), filtered and concentrated *in vacuo* to a brown oil. The crude product was purified by column chromatography (Grace Resolve™ 80 g, 150 mL silica cartridge; 1:0 hexane–ether for 5 min then to 3:7 over 120 min and holding at this solvent mixture until elution was complete), loading the sample in DCM, to give the products as a white, crystalline solids; 2-Phenyl-2/3-[¹³C]-imidazo[1,2-*a*]pyridine ([¹³C]-3a) (0.03 g, 0.14 mmol, 20%) and 3-Phenyl-3-[¹³C]-imidazo[1,2-*a*]pyridine ([¹³C]-4a) (0.04 g, 0.21 mmol, 30%).

2-Phenyl-2/3-[¹³C]-imidazo[1,2-*a*]pyridine ([¹³C]-3a)

*R*_f 0.55 (4:1 ether–petrol); δ_H (400 MHz, CDCl₃; Me₄Si) 8.09 (1H, dt, H5 *J* 6.8, *J* 1.2), 7.97–7.93 (2H, m, H2'/H6'), 7.84 (0.82H, dd, H3 *J* 8.4, *J* 0.8), 7.84 (0.18H, d, H3 *J* 190.7) 7.63 (1H, d, H8 *J* 9.2), 7.43 (2H, *t*_{app.}, H3'/H5' *J* 8.0), 7.32 (1H, t, H4' *J* 7.6), 7.15 (1H, ddd, H7 *J* 9.2, *J* 6.6, *J* 1.2), 6.75 (1H, dt_{app.}, H6 *J* 6.6, *J* 0.8); δ_C (100 MHz, CDCl₃; Me₄Si) 145.82 (C2-label), 145.47 (d, C9 *J* 4.5), 133.76 (d, C1' *J* 67.9), 133.76 (s, C1'), 128.82 (d, C3'/C5' *J* 4.4), 128.82 (s, C3'/C5'), 128.08 (s, C4'), 126.14 (d, C2'/C6' *J* 2.5), 125.66 (d, C5 *J* 7.9), 125.66 (s, C5), 124.79 (C7), 117.62 (d, C8 *J* 6.1), 117.62 (s, C8) 112.55 (C6), 108.21 (C3-label); *m/z* (CI) 196 ([M + H]⁺, 100%), 184 (12). Found: [M + H]⁺, 196.0947. C₁₂¹³C₁H₁₁N₂ requires 196.0950.

3-Phenyl-3-[¹³C]-imidazo[1,2-*a*]pyridine ([¹³C]-4a)

*R*_f 0.13 (4:1 ether–petrol); δ_H (400 MHz, CDCl₃; Me₄Si) 8.31 (1H, dd, H5 *J* 6.8, *J* 1.2), 7.68 (1H, od, H2 *J* 12.4), 7.65 (1H, od, H8 *J* 8.8), 7.55–7.52 (2H, m, H2'/H6'), 7.49 (2H, *t*_{app.}, H3'/H5' *J* 8.0), 7.39 (1H, tt, H4' *J* 7.2, *J* 1.2), 7.17 (1H, ddd, H7 *J* 9.2, *J* 6.4, *J* 1.2), 6.86 (1H, *t*_{app.}, H6 *J* 6.8); δ_C (100 MHz, CDCl₃; Me₄Si) 146.21 (d, C9 *J* 9.1), 132.57 (d, C2 *J* 69.0), 132.52 (s, C9), 129.40 (d, C1' *J* 67.4), 129.33 (d, C3'/C5' *J* 4.2), 129.33 (s, C3'/C5'), 128.27 (s, C4'), 128.11 (d, C2'/C6' *J* 2.7), 125.84 (C3-label), 124.34 (s, C7), 123.43 (s, C5), 118.09 (C8), 113.30 (C6); *m/z* (CI) 196 ([M + H]⁺, 100%). Found: [M + H]⁺, 196.0945. C₁₂¹³C₁H₁₁N₂ requires 196.0950.

X-ray crystal structures are available for compounds **3a**, **3a·HCl·2H₂O**, **4a·HCl·2H₂O** and **7** (see ESI[†]). CCDC 907271–907274 contain the supplementary crystallographic data for this paper.

[†]Due to volatility, solvent could not be fully removed; yield calculated from ¹H-NMR.



We thank sanofi-aventis, Newcastle University and the EPSRC (equipment grant EP/F03637X/1) for funding. We also thank Prof. W. McFarlane and Dr C. Wills for contributions in the field of NMR and the EPSRC National Mass Spectrometry Service Centre, Swansea, UK.

Notes and references

- S. A. Galton and F. M. Beringer, *J. Org. Chem.*, 1965, **30**, 1930–1934.
- T. Wirth, M. Ochiai, A. Varvoglis, V. V. Zhdankin, G. F. Koser, H. Tohma and Y. Kita, *Hypervalent Iodine Chemistry*, Springer, London, 2003.
- P. J. Stang, *Angew. Chem., Int. Ed. Engl.*, 1992, **31**, 274–285.
- T. Wirth, *Angew. Chem., Int. Ed.*, 2005, **44**, 3656–3665.
- P. J. Stang and V. V. Zhdankin, *Chem. Rev.*, 1996, **96**, 1123–1178.
- V. V. Zhdankin and P. J. Stang, *Chem. Rev.*, 2002, **102**, 2523–2584.
- P. J. Stang, *J. Org. Chem.*, 2003, **68**, 2997–3008.
- T. Kitamura and Y. Fujiwara, *Org. Prep. Proced. Int.*, 1997, **29**, 409–458.
- T. Wirth and U. H. Hirt, *Synthesis*, 1999, 1271–1287.
- V. V. Zhdankin and P. J. Stang, *Tetrahedron*, 1998, **54**, 10927–10966.
- T. Kitamura, Y. Mansei and Y. Fujiwara, *J. Organomet. Chem.*, 2002, **646**, 196–199.
- A. Varvoglis, E. Kotali and A. Bozopoulos, *J. Chem. Soc., Perkin Trans. 1*, 1989, 827–832.
- P. J. Stang and P. Murch, *Tetrahedron Lett.*, 1997, **38**, 8793–8794.
- G. Maas, M. Regitz, U. Moll, R. Rahm, F. Krebs, R. Hector, P. J. Stang, C. M. Crittall and B. L. Williamson, *Tetrahedron*, 1992, **48**, 3527–3540.
- P. J. Stang, P. Murch and A. M. Arif, *J. Org. Chem.*, 1997, **62**, 5959–5965.
- P. J. Stang, B. L. Williamson and A. M. Arif, *J. Am. Chem. Soc.*, 1993, **115**, 2590–2597.
- M. Shimizu, Y. Takeda and T. Hiyama, *Chem. Lett.*, 2008, 1304–1305.
- P. J. Stang, B. L. Williamson and R. R. Tykwinski, *J. Am. Chem. Soc.*, 1994, **116**, 93–98.
- M. Ochiai, M. Kunishima, S. Tani and Y. Nagao, *J. Am. Chem. Soc.*, 1991, **113**, 3135–3142.
- K. S. Feldman, M. M. Bruendl and K. Schildknegt, *J. Org. Chem.*, 1995, **60**, 7722–7723.
- I. F. D. Hyatt and M. P. Croatt, *Angew. Chem., Int. Ed.*, 2012, **51**, 7511–7514.
- K. Banert, R. Arnold, M. Hagedorn, P. Thoss and A. A. Auer, *Angew. Chem., Int. Ed.*, 2012, **51**, 7515–7518.
- P. J. Stang, B. W. Surber, Z. C. Chen, K. A. Roberts and A. G. Anderson, *J. Am. Chem. Soc.*, 1987, **109**, 228–235.
- G. F. Koser, L. Rebrovic and R. H. Wettach, *J. Org. Chem.*, 1981, **46**, 4324–4326.
- T. Kitamura and P. J. Stang, *J. Org. Chem.*, 1988, **53**, 4105–4106.
- P. J. Stang and V. V. Zhdankin, *J. Am. Chem. Soc.*, 1990, **112**, 6437–6438.
- M. D. Bachi, N. Barner, C. M. Crittall, P. J. Stang and B. L. Williamson, *J. Org. Chem.*, 1991, **56**, 3912–3915.
- V. V. Zhdankin, R. Tykwinski, R. Caple, B. Berglund, A. S. Kozmin and N. S. Zefirov, *Tetrahedron Lett.*, 1988, **29**, 3717–3720.
- V. V. Zhdankin, R. Tykwinski, B. Berglund, M. Mullikin, R. Caple, N. S. Zefirov and A. S. Kozmin, *J. Org. Chem.*, 1989, **54**, 2609–2612.
- Y. Ishiwata and H. Togo, *Synlett*, 2008, 2637–2641.
- V. V. Zhdankin, P. J. Persichini, R. Cui and Y. Jin, *Synlett*, 2000, 719–721.
- V. V. Zhdankin, C. J. Kuehl, A. P. Krasutsky, J. T. Bolz and A. J. Simonsen, *J. Org. Chem.*, 1996, **61**, 6547–6551.
- G. F. Koser, G. P. Sun, C. W. Porter and W. J. Youngs, *J. Org. Chem.*, 1993, **58**, 7310–7312.
- M. Ochiai, Y. Masaki and M. Shiro, *J. Org. Chem.*, 1991, **56**, 5511–5513.
- J. P. Brand, J. Charpentier and J. Waser, *Angew. Chem., Int. Ed.*, 2009, **48**, 9346–9349.
- S. Nicolai, S. Erard, D. F. Gonzalez and J. Waser, *Org. Lett.*, 2010, **12**, 384–387.
- E. B. Merkushev, L. G. Karpitskaya and G. I. Novosel'tseva, *Dokl. Akad. Nauk SSSR*, 1979, **245**, 607–610.
- L. I. Dixon, M. A. Carroll, T. J. Gregson, G. J. Ellames, R. W. Harrington and W. Clegg, *Eur. J. Org. Chem.*, 2013, 2334–2345.
- L. I. Dixon, M. A. Carroll, T. J. Gregson, G. J. Ellames, R. W. Harrington and W. Clegg, *Org. Synth.*, 2013, in press.
- Z. Liu, Z. C. Chen and Q. G. Zheng, *Synth. Commun.*, 2004, **34**, 361–367.
- M. Ueno, T. Nabana and H. Togo, *J. Org. Chem.*, 2003, **68**, 6424–6426.
- Y. Y. Xie, Z. C. Chen and Q. G. Zheng, *J. Chem. Res., Synop.*, 2003, 614–615.
- B. B. Toure, B. S. Lane and D. Sames, *Org. Lett.*, 2006, **8**, 1979–1982.
- C. Enguehard, J.-L. Renou, V. Collot, M. Hervet, S. Rault and A. Gueiffier, *J. Org. Chem.*, 2000, **65**, 6572–6575.
- T. Kitamura and P. J. Stang, *Tetrahedron Lett.*, 1988, **29**, 1887–1890.
- P. J. Stang, H. Wingert and A. M. Arif, *J. Am. Chem. Soc.*, 1987, **109**, 7235–7236.
- M. Ochiai, M. Kunishima, K. Fuji and Y. Nagao, *J. Org. Chem.*, 1988, **53**, 6144–6145.
- M. Yoshida and S. Hara, *Org. Lett.*, 2003, **5**, 573–574.
- M. Yoshida, A. Komata and S. Hara, *J. Fluorine Chem.*, 2004, **125**, 527–529.
- M. Ochiai, K. Uemura, K. Oshima, Y. Masaki, M. Kunishima and S. Tani, *Tetrahedron Lett.*, 1991, **32**, 4753–4756.
- M. Ochiai, Y. Kitagawa, M. Toyonari, K. Uemura, K. Oshima and M. Shiro, *J. Org. Chem.*, 1997, **62**, 8001–8008.
- S. Hara, M. Yoshida, T. Fukuhara and N. Yoneda, *Chem. Commun.*, 1998, 965–966.



- 53 M. Yoshida, A. Komata and S. Hara, *Tetrahedron*, 2006, **62**, 8636–8645.
- 54 T. Guan, M. Yoshida, D. Ota, T. Fukuhara and S. Hara, *J. Fluorine Chem.*, 2005, **126**, 1185–1190.
- 55 M. Ochiai, Y. Nishi and M. Hirobe, *Tetrahedron Lett.*, 2005, **46**, 1863–1866.
- 56 T. L. Ross, J. Ermert, C. Hocke and H. H. Coenen, *J. Am. Chem. Soc.*, 2007, **129**, 8018–8025.
- 57 P. Wipf and S. Venkataraman, *J. Org. Chem.*, 1996, **61**, 8004–8005.
- 58 K. Miyamoto, Y. Nishi and M. Ochiai, *Angew. Chem., Int. Ed.*, 2005, **44**, 6896–6899.
- 59 M. A. Carroll, S. Martin-Santamaria, V. W. Pike, H. S. Rzepa and D. A. Widdowson, *J. Chem. Soc., Perkin Trans. 2*, 1999, 2707–2714.
- 60 T. Okuyama, S. Imamura and M. Fujita, *J. Org. Chem.*, 2006, **71**, 1609–1613.
- 61 M. Ochiai, M. Kida, K. Sato, T. Takino, S. Goto, N. Donkai and T. Okuyama, *Tetrahedron Lett.*, 1999, **40**, 1559–1562.
- 62 P. Kowalski and J. Korchowiec, *J. Mol. Struct. (THEOCHEM)*, 1993, **288**, 119–131.
- 63 S. Nikas, N. Rodios and A. Varvoglis, *Molecules*, 2000, **5**, 1182–1186.
- 64 P. J. Stang, *Chem. Eng. News*, 1989, **67**, 4.
- 65 D. B. Dess and J. C. Martin, *J. Am. Chem. Soc.*, 1991, **113**, 7277–7287.
- 66 H. Tohma, S. Takizawa, T. Maegawa and Y. Kita, *Angew. Chem.*, 2000, **112**, 1362–1364.
- 67 H. J. Lucas and E. R. Kennedy, *Org. Synth. Coll. Vol.*, 1955, **3**, 485–487.
- 68 J. S. Yadav, B. V. Subba Reddy, Y. Gopal Rao, M. Srinivas and A. V. Narsaiah, *Tetrahedron Lett.*, 2007, **48**, 7717–7720.
- 69 S. Kumar and D. P. Sahu, *ARKIVOC*, 2008, 88–98.
- 70 R. Adams and I. J. Patcher, *J. Am. Chem. Soc.*, 1954, **76**, 1845–1847.
- 71 Gol'dfarb and Kondakowa, *Zh. Prikl. Khim.*, 1942, **15**, 151–158.
- 72 E. S. Hand and W. W. Paudler, *Tetrahedron*, 1982, **38**, 49–56.
- 73 V. A. Artyomov, A. M. Shestopalov and V. P. Litvinov, *Synthesis*, 1996, 927–929.
- 74 E. J. Corey and P. L. Fuchs, *Tetrahedron Lett.*, 1972, 3769–3772.

